US EditioniOnctura commences randomized Phase I/II study in non-small cell lung cancer - PressReach
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
iOnctura commences randomized Phase I/II study in non-small cell lung cancer - PressReach
First patient dosed in study investigating roginolisib + dostarlimab +/- docetaxel in patients with NSCLC who have progressed on prior immunotherapy/chemo Study will evaluate safety of the combination and explore whether targeting PI3Kδ with immunotherapy may rebalance the immune system to prevent or reverse resistance to current standard immunotherapy/chemo in NSCLC GENEVA and AMSTERDAM, May 8, 2025 /PRNewswire/ — iOnctura, a clinical-stage bio…
iOnctura commences randomized Phase I/II study in non-small cell lung cancer – Optimum Strategic CommunicationsLink to: Alchemab Therapeutics signs landmark $415m licensing agreement for ATLX-1282 with Eli Lilly and CompanyScroll to top
First patient dosed in study investigating roginolisib + dostarlimab +/- docetaxel in patients with NSCLC who have progressed on prior immunotherapy/chemo Study will evaluate safety of the combination and explore whether targeting PI3Kδ with immunotherapy may rebalance the immune system to prevent or reverse resistance to current standard immunotherapy/chemo in NSCLC Geneva, Switzerland and Amsterdam, […]
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
